GSK Secures FDA Approval for Jideytro in Lung Cancer Treatment

The regulatory green light arrives ahead of the anticipated September deadline, bolstered by data from the ARROS-1 phase I/II clinical trial. The study, which evaluated 117 patients, reported an objective response rate of 44%, with significant durability noted at the six and 12-month marks. Researchers highlighted the drug’s ability to maintain efficacy in patients with brain metastases and specific resistance mutations, addressing critical gaps in current care standards.

Designed as a selective inhibitor, Jideytro aims to improve patient outcomes by combining high target specificity with the ability to penetrate the blood-brain barrier. Common side effects reported during the trial included fatigue, peripheral neuropathy, and edema. For the estimated 50,000 individuals diagnosed annually with this form of lung cancer, the therapy offers a specialized option to manage disease progression. GSK is now looking to expand its oncology footprint further, with additional pipeline candidates for ALK-altered and HER2-altered cancers currently moving through regulatory and clinical review.